Imfinzi, in combination with chemotherapy, reduces recurrence risk by 32% and death risk by 25% compared to chemotherapy alone for muscle-invasive bladder cancer in the NIAGARA Phase III trial. Positive results show significant improvement in event-free survival and overall survival.